Author | Investigated SNP (rsID) | No of patients | Genetic variant carriers | CTRCT definition | Total CTRCT events | Case- Eventsa | Control-Eventsb | OR | 95%CI | p value |
---|---|---|---|---|---|---|---|---|---|---|
Gómez Peña et al. [15] | 1,136,201 (HER2 655 A > G) | 78 | 28 (35.6%) | LVEF↓ > 10% resulting < 50%; or LVEF↓ > 15%; or any LVEF↓, resulting < 45%; or CHF | 9 (32.1%) | 9/28 (32.1%) | 6/50 (12%) | 3.41 | 1.02–11.96 | 0.039 |
Beauclair et al. [16] | 1,136,201 (HER2 655 A > G) | 61 | 25 (41%) | LVEF↓ > 20% | 5 (8.2%) | 5/25 (20%) | 0 | NA | NA | 0.004 |
Lemieux et al. [17] | 1,136,201 (HER2 655 A > G) | 73 | 21 (29%) | LVEF↓ > 10% resulting < 50%; or any LVEF↓, resulting < 45%; | 10 (13.7%) | 6/21 (28.6%) | 4/52 (7.7%) | 4.67 | 1.01–19.94 | 0.028 |
Roca L et al. [2] | 1,136,201 (HER2 655 A > G) | 132 | 53 (40%) | Any LVEF↓ resulting < 50%; or LVEF↓ > 15%; or discontinuation of trastuzumab due to CTRCT | 13 (9.8%) | 9/53 (16.9%) | 4/79 (5%) | 3.79 | 1.09–14.01 | 0.026 |
Tan et al. [18] | 1,136,201 (HER2 655 A > G) | 91 | 27 (29.7%) | LVEF↓ > 10% resulting < 53%; or CHF; or ACS; or fatal arrhythmia | 26 (28.6%) | 13/27 (48.1%) | 13 (20.3%) | 7.99 | 1.79–35.76 | 0.007 |
Peddi et al. [19] | 1,136,201 (HER2 655 A > G) | 662 | 238 (35.5%) | LVEF↓ > 10%; or CHF | 115 (17.3%) | 47/238 (19.7%) | 68/424 (16%) | NA | NA | 0.65 |
Stanton et al. [20] | 1,058,808 (HER2 1170 C > G) | 140 | 111 (79.3%) | LVEF↓ > 15%; or CHF | 29 (21%) | 19/111 (17.1%) | 10/29 (34.5%) | 2.60 | 1.02–6.62 | 0.004 |
Boekhout et al. [21] | 1,058,808 (HER2 1170 C > G) | 206 | NA | LVEF↓ > 15%; or LVEF < 45% | 36 (17.4%) | NA | NA | 0.09 | 0.02–0.45 | 0.003 |